Bliss GVS Pharma Ltd
NSE:BLISSGVS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Bliss GVS Pharma Ltd
Net Income (Common)
Bliss GVS Pharma Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bliss GVS Pharma Ltd
NSE:BLISSGVS
|
Net Income (Common)
₹1.1B
|
CAGR 3-Years
8%
|
CAGR 5-Years
9%
|
CAGR 10-Years
5%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Net Income (Common)
₹55.7B
|
CAGR 3-Years
15%
|
CAGR 5-Years
21%
|
CAGR 10-Years
11%
|
|
|
Cipla Ltd
NSE:CIPLA
|
Net Income (Common)
₹45.5B
|
CAGR 3-Years
20%
|
CAGR 5-Years
15%
|
CAGR 10-Years
10%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Net Income (Common)
₹109.2B
|
CAGR 3-Years
37%
|
CAGR 5-Years
35%
|
CAGR 10-Years
11%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Net Income (Common)
₹46.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
32%
|
CAGR 10-Years
8%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Net Income (Common)
₹22.7B
|
CAGR 3-Years
40%
|
CAGR 5-Years
13%
|
CAGR 10-Years
4%
|
|
Bliss GVS Pharma Ltd
Glance View
Bliss GVS Pharma Ltd. engages in the development, manufacture, and marketing of pharmaceutical formulations. The company is headquartered in Mumbai, Maharashtra and currently employs 750 full-time employees. The company went IPO on 2010-07-26. The firm offers a range of suppositories, tablets, suspensions and injections to various therapeutic segments, including antimalarial, antifungal, dermatological, contraceptive, laxative, anti-hemorrhoidal, antispasmodic, antibiotic, antimicrobial antipyretic, analgesic and anti-inflammatory. The firm's pharma products include capsules, creams, gels, ointments, dry powder for injection, effervescent tablets, eye/ear drops, nasal solution, lotions, lozenges, soft gelatin capsules and syrups. its other healthcare products include balm, nasal inhaler, solution, soap, vaginal wash, roll on, shampoo, powder, spray and petroleum jelly. The firm offers its products under various brands, which include Lonart, Funbact, P-Alaxin, Lofnac, Amoxicillin, Antiderm Extra Plus and Esmazole. Its product portfolio comprises over 250 branded formulations across 20 therapeutic segments.
See Also
What is Bliss GVS Pharma Ltd's Net Income (Common)?
Net Income (Common)
1.1B
INR
Based on the financial report for Dec 31, 2025, Bliss GVS Pharma Ltd's Net Income (Common) amounts to 1.1B INR.
What is Bliss GVS Pharma Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
5%
Over the last year, the Net Income (Common) growth was 83%. The average annual Net Income (Common) growth rates for Bliss GVS Pharma Ltd have been 8% over the past three years , 9% over the past five years , and 5% over the past ten years .
